Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01045863 · ClinicalTrials.gov registry record · Phase 1
To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01045863 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 10 participants.
The verdict
NCT01045863, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety and tolerability after a single administration of PF-03382792 in healthy volunteers.; and to evaluate plasma drug levels and biological activity.
Interventions
- DRUG PF-03382792 Cohort 1
- DRUG PF-03382792 Cohort 2
- DRUG PF-03382792
- DRUG Food Effect cohort
- DRUG CSF cohort
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01045863
The ClinicalTrials.gov registry entry for NCT01045863 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which PF-03382792 Cohort 1 is the first listed.
NCT01045863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01045863 about?
NCT01045863 is a clinical study titled "To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers". The purpose of this study is to evaluate safety and tolerability after a single administration of PF-03382792 in healthy volunteers.; and to evaluate plasma drug levels and biological activity.
What is the current status of trial NCT01045863?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2010-02. Estimated completion is 2010-06.
What interventions are being tested in trial NCT01045863?
The interventions under investigation include: PF-03382792 Cohort 1 (DRUG), PF-03382792 Cohort 2 (DRUG), PF-03382792 (DRUG), Food Effect cohort (DRUG), CSF cohort (DRUG).
Who is sponsoring clinical trial NCT01045863?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.